☰

Brenus Pharma

Scaling an off-the-shelf cancer vaccine platform

Industry
Biotechnology — Oncology Cell Therapy
Headquarters
Lyon, France
Public information as of
March 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Brenus Pharma's published strategy and is not endorsed by, or produced in cooperation with, Brenus Pharma. Company website

Strategic priorities

Brenus Pharma is a clinical-stage French biotech developing allogeneic, off-the-shelf cancer vaccines from its Stimulated Tumor Cell (STC) platform, with a lead candidate STC-1010 in colorectal cancer and a pipeline that extends to ovarian cancer (STC-1020) and other solid tumor indications. The platform applies precise physical and chemical stressors to human cell lines to generate a proteomic fingerprint of more than 200 tumor antigens, and the company is now scaling from lab-scale R&D to batch sizes intended for 100 or more patients. A September 2024 Series A of €22.2 million, led by Angelor alongside UI Investissement, Noshaq, Investsud and BIOJAG, funds the move into GMP-compliant industrial bioproduction.

The BreAK-CRC Phase I/IIa trial is running across four French oncology centers — CGFL Dijon, Institut Bergonié Bordeaux, ICM Montpellier and Hospices Civils de Lyon — with clinical expansion to Belgium and the United States planned for 2026 to 2027 and an IND filing targeted by 2027. Brenus generates large volumes of multi-omics data from this trial, including cytokine profiles, immunophenotyping, ctDNA dynamics and tertiary lymphoid structure evolution, which the company needs to correlate with manufacturing parameters to identify the critical quality attributes the FDA will look for at any future site transfer.

The operational footprint is expanding alongside the clinical program. The French headquarters is in Lyon, with R&D activities in Clermont-Ferrand, and a new R&D branch was established in Liège, Belgium in 2025 with backing from Noshaq and Investsud, located at Avenue Hippocrate 5. The Liège site is greenfield: laboratory infrastructure is being built from scratch, and the design choices made now will determine whether it integrates cleanly with the French sites or repeats the data fragmentation that already exists across Lyon and Clermont-Ferrand.

Closely linked to that industrialization is the InSphero collaboration known as Project Allogenix, funded through a €1.5 million Eurostars grant, which develops 3D tumor spheroid models co-cultured with fibroblasts for potency testing. The FDA now expects validated potency assays as early as Phase I for cell-based therapies, and 74 percent of similar cell therapy programs have stalled on chemistry, manufacturing and controls deficiencies — making the digital evidence behind comparability after any manufacturing change a question of program continuity, not of process preference.

Challenges we see

  • Manufacturing Manufacturing

    Maintaining batch consistency across stressor applications

    The STC process requires applying precise physical stressors (irradiation, heat shock) and chemical stressors to human cell lines to generate a proteomic fingerprint of more than 200 tumor antigens. As batch sizes move toward 100 or more patients per run, even small deviations in stressor application produce batches that fail to meet specifications.

    At industrial batch sizes, the operating envelope of the STC process becomes a property of the production line rather than of the operator. Capturing each stressor parameter as it is applied gives the same view of the process to the engineers, the production team and the quality organisation.

  • Digital Integration

    Unifying multi-omics data across production and analysis

    The BreAK-CRC trial generates large volumes of multi-omics data — cytokine profiles, immunophenotyping, ctDNA dynamics, tertiary lymphoid structure evolution — from instruments and laboratory systems that sit separately from the OT data captured on the STC production line. Brenus applies deep learning to neoantigen and protein validation but currently feeds those models with data that has been moved between systems by hand.

    Where OT-side stimulation data and IT-side multi-omics data live in separate estates, every translational question requires a new extract. Routing both through one model would make correlation between manufacturing parameters and clinical biomarkers a query rather than a project.

  • Compliance Regulatory

    Producing digital comparability evidence for potency assays

    The FDA now expects validated potency assays as early as Phase I for cell-based therapies, and 74 percent of similar programs have stalled on CMC deficiencies. The new 3D spheroid models from the InSphero collaboration carry comparability obligations once the Liège site is commissioned and once the manufacturing process is scaled.

    Comparability after any manufacturing change depends on a digital evidence chain that ties a potency result back to the imaging run, the assay version and the batch record. Where that chain is paper, the review at IND filing becomes a reconstruction rather than a read.

  • Operations Operations

    Designing the Liège site as a digital-first facility

    Brenus opened a new R&D branch in Liège, Belgium in 2025 at Avenue Hippocrate 5, with backing from Noshaq and Investsud. The site is being built from scratch to support next-generation research into solid tumor indications and needs to work as one operation with Lyon and Clermont-Ferrand.

    What is specified in advance at a greenfield site — equipment data contracts, network segmentation, the laboratory execution system — sets the baseline for a decade. Building that baseline on paper would mean re-doing it in three years when the first production change arrives.

  • Digital Regulatory

    Coordinating data flows across France, Belgium and the planned US footprint

    Brenus operates across Lyon, Clermont-Ferrand and Liège, with planned US expansion in 2026 to 2027. Production and clinical trial data have to be reachable across jurisdictions that bring their own obligations under GDPR, HIPAA and the EU NIS2 directive on cybersecurity. The existing IT/OT estate is heterogeneous: instruments from different vendors do not natively communicate, and the platform team compensates with manual transcription.

    As the footprint crosses borders, the data path between a centrifuge in one country and a dashboard in another becomes a security control rather than a convenience. Specifying identity, segmentation and protocol choice now is what makes later expansion a deploy rather than a redesign.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Real-time monitoring of stressor application on the STC line

    Quality control on the STC production line relies on semi-automated controls and on testing after the fact. Labor accounts for approximately 50 percent of cost of goods in cell therapy without Industry 4.0 interventions, and any deviation in stressor application produces a batch that does not meet the proteomic fingerprint.

    Instrumenting irradiators, heat-shock equipment and chemical dosing systems with IoT sensors exposed via OPC UA (Open Platform Communications Unified Architecture) turns every stressor parameter into a value that is recorded as it is applied, giving the production team a reproducible digital record of each batch.

    • Brenus Pharma Series A press release, September 2024
    • Brenus Pharma — Stimulated Tumor Cell platform description

  2. Putting production, multi-omics and clinical data into one model

    Multi-omics data from the BreAK-CRC trial — cytokine profiles, immunophenotyping, ctDNA, tertiary lymphoid structure evolution — lives in instruments and laboratory systems that are separated from the OT data captured on the STC line. Scientists cannot correlate manufacturing parameters with clinical biomarkers without commissioning a new extract, and the deep learning models used for neoantigen validation work from pieced-together feeds.

    A shared ontology describing batch, sample, assay, result, stimulus and clinical outcome lets Brenus query production and clinical data in one place, which is what correlating a clinical result with the batch that produced it actually requires.

    • Brenus-InSphero Allogenix project, Eurostars grant
    • Brenus Pharma Series A investor materials, September 2024

  3. Computer vision for 3D spheroid potency analysis

    The InSphero collaboration produces cryopreserved 3D tumor spheroids co-cultured with fibroblasts for potency testing. Counting apoptotic events in image data is currently manual, which makes the results operator-dependent and limits the digital evidence available for FDA comparability reviews.

    An image-analysis pipeline over microscopy output, with each result written into the GxP quality record with its instrument, method version and timestamp, replaces subjective counting with a reproducible measurement and the evidence trail that comparability exercises require.

    • Brenus-InSphero Allogenix project, Eurostars grant
    • FDA guidance on potency assays for cell-based therapies

  4. Digital-first design for the Liège greenfield site

    The new R&D branch in Liège, Belgium, established in 2025 at Avenue Hippocrate 5, is being built from scratch with backing from Noshaq and Investsud. Equipment selections, network segmentation and laboratory system choices made now will determine whether the site integrates with Lyon and Clermont-Ferrand or repeats the data fragmentation already present there.

    Specifying the IT/OT architecture, equipment data contracts and laboratory execution system before procurement means interoperability and traceability arrive with the building rather than becoming an integration project after handover.

    • Brenus R&D branch in Liège, Belgium, 2025
    • Noshaq and Investsud investment announcements, 2025

  5. Secure multi-site connectivity for cross-border operations

    Brenus operates across Lyon, Clermont-Ferrand, Liège and planned US sites, with instruments from different vendors that do not natively communicate. Production and clinical data have to be shared across jurisdictions governed by GDPR, HIPAA and the EU NIS2 directive on cybersecurity, and the existing IT/OT estate is heterogeneous.

    An identity-based and segmented connectivity architecture, with a documented protocol and data contract for each instrument class, makes cross-border data flow a designed property rather than a workaround, and gives the security and compliance teams a current view of who is accessing what.

    • Brenus Pharma multi-site footprint, 2025
    • EU NIS2 cybersecurity directive, 2024

What we'd propose

  • Digital CDMO

    Real-time digitalization of the STC production line

    We instrument the STC production line with IoT sensors, connect irradiators, heat-shock equipment and chemical dosing systems through OPC UA, and stream every stressor parameter into a per-batch digital record so the production team has the same view of the process as the equipment.

    • Sensor and control integration

      Getting data off the line

      Connect irradiators, heat-shock equipment and dosing systems through OPC UA or MQTT so stressor parameters leave the equipment in a documented, vendor-neutral form rather than being read from a panel and transcribed.

    • Real-time batch monitoring

      Alerts while the batch runs

      Build the normal operating envelope for each stressor from historical runs, then flag drift against the current batch so operators see a quality signal in minutes instead of a result in a later report.

    • Electronic batch record

      Evidence assembled as you go

      Write monitored parameters into a per-batch record with lineage back to the instrument that produced each value, generating the digital evidence that an FDA comparability review would otherwise need to reconstruct.

    • Each stressor parameter is captured as it is applied, so the production record is generated by the line rather than compiled from it.
    • Drift against the operating envelope is visible in the same shift that the batch is running, not in the next inspection.
    • Comparability evidence is built continuously, which is what the planned scale-up and the Liège site commissioning both require.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Ontology-driven data platform for production and clinical data

    An ontology-based data platform that defines batch, sample, assay, result, stimulus and clinical outcome once, then loads STC production data, potency assay data and BreAK-CRC trial biomarkers against the same model so production and clinical questions can be answered in one place.

    • Shared STC and clinical ontology

      One agreed set of terms

      Define batch, sample, stimulus, assay, result and clinical outcome as explicit entities with agreed relationships, so a query written once returns comparable answers across production and clinical data rather than two dialects of the same table.

    • Pipelines from instruments and laboratory systems

      Loading both sides

      Build ingestion for STC line OT data, InSphero 3D spheroid output and the BreAK-CRC multi-omics feeds, with schema validation at the boundary so missing or malformed records fail loudly instead of silently.

    • Translational analytics and dashboards

      Questions answered without IT tickets

      Expose the model through scientist-facing dashboards and a query layer so the team can correlate a clinical outcome with the batch and the stimuli that produced it without commissioning a new extract for each study.

    • Integration work is done once against a shared model rather than once per point-to-point interface.
    • Manufacturing parameters and clinical biomarkers can be queried together, which is what identifying the critical quality attributes of the STC platform actually requires.
    • New assays and new sites attach to the model rather than triggering another migration.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Computer vision for 3D spheroid potency assay

    An image-analysis pipeline over microscopy output from the InSphero 3D tumor spheroid collaboration, with each potency result written into the GxP quality record with its instrument, method version and timestamp, replacing subjective manual counting with a reproducible, validated measurement.

    • Microscopy instrument integration

      Images captured at source

      Connect the microscopy equipment through OPC UA so images are captured at defined timepoints with instrument identity and method version attached, removing the operator variability introduced by manual image selection and focusing.

    • Image-based potency quantification

      Reproducible counting

      Run the captured images through a model trained on annotated spheroid datasets, returning apoptotic counts and potency scores with confidence intervals that meet the statistical expectations of an FDA comparability review.

    • GxP audit trail linkage

      Evidence that holds up

      Write the potency result, the raw images and the model version into the electronic batch record with a 21 CFR Part 11 compliant audit trail, so the comparability evidence for the planned scale-up and the Liège site is generated by the workflow rather than assembled for it.

    • Potency counting becomes reproducible across operators and across sites.
    • Comparability evidence is produced by the workflow rather than reconstructed for each review.
    • Scientist time moves from manual counting to designing the next assay.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Digital-first architecture for the Liège greenfield site

    An architecture and standards package for the new R&D branch in Liège, Belgium: IT/OT reference design, network segmentation, equipment data contracts and laboratory execution system specified before procurement, so the site's data path is designed rather than assembled from what arrives.

    • IT/OT reference architecture for the site

      One documented data path

      Specify how laboratory equipment, the laboratory execution system, the production data platform and the headquarters applications connect, including the segmentation model, so every vendor on the project builds toward the same target.

    • Equipment data contracts

      What each instrument must publish

      Write the OPC UA information models and topic structures into procurement requirements, making interoperability a purchase condition rather than an integration project after handover.

    • Paperless laboratory operations

      End-to-end digital workflow

      Deploy a laboratory execution system with barcode-driven sample tracking, electronic signatures and automated instrument data capture, so the Liège site operates on validated data from day one and serves as the template for Lyon and Clermont-Ferrand.

    • Interoperability is bought with the equipment rather than built after commissioning.
    • Traceability from sample to result is a property of the design, not a later addition.
    • The same architecture is the template for upgrading the French sites, not a separate codebase.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for CMC and regulatory documentation

    Narrow, reviewable agents that take the repetitive part of Brenus's CMC and regulatory documentation: drafting comparability summaries from source records, checking a submission against its template before review, and identifying every controlled document a standards change touches. A named person approves every output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of a CMC section, a comparability summary or a site-transfer document from the underlying production and assay records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against the FDA or EMA template and the site's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Change impact across the document set

      Which documents a change touches

      When a standard, an assay or a manufacturing process changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Review queues move faster because documents arrive complete rather than incomplete.
    • The scope of a standards change is established by search rather than by recollection.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Where QB Systems fits

Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.

Scale
Benchtop (1–8 L)

Glass vessels with the complete hardware and software stack. This is the core range for development work.

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Brenus Pharma's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Manufacturing Automation 25 → 80
Stressor application on the STC production line is semi-automated with batch records that lean on manual transcription. As batches move toward 100 or more patients per run, the production team will need process values captured by the line rather than recorded by hand.
Data Integration & Analytics 20 → 85
OT-side stimulation data and IT-side multi-omics data currently exchange through manual steps, and the deep learning models used for neoantigen validation work from pieced-together feeds. A shared model would let translational questions be answered as queries.
Quality & Compliance 30 → 85
The InSphero 3D spheroid collaboration is partially modernized, but potency counting is still manual and the digital evidence behind comparability reviews is limited. The 74 percent figure for cell therapy programs stalling on CMC deficiencies sets the urgency.
IT/OT Infrastructure 15 → 75
Laboratory equipment from different vendors does not natively communicate, and the three existing sites are run on separate infrastructure. The Liège site is greenfield, which is the opportunity to set the standard that the French sites can then adopt.
Cybersecurity & Access 20 → 80
Cross-border operations across France, Belgium and the planned US footprint bring GDPR, HIPAA and the EU NIS2 directive into scope. Identity-based access control and a documented segmentation model are what make the planned US expansion a deploy rather than a redesign.
Process Intelligence 10 → 70
Stressor-to-outcome correlation is currently retrospective and manual, and the predictive bioprocess model Brenus indicates as a strategic priority is not yet in place. A shared data platform is the prerequisite for the digital twin work to follow.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of March 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Brenus Pharma, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].